Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.58 |
| ▸ | HPGD | P15428 | 3/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.58 |
| ▸ | CES2 | O00748 | 2/20 | 0.52 |
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | LIPC | P11150 | 1/20 | 0.48 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | SORT1 | Q99523 | 8/20 | 0.46 |
| ▸ | KDM1A | O60341 | 1/20 | 0.46 |
| ▸ | TAS2R14 | Q9NYV8 | 2/20 | 0.44 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.44 |
| ▸ | PIM1 | P11309 | 1/20 | 0.44 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.44 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL426615 | 0.85 | ALDH1A1 (0.62) | ALDH1A1HPGDKDM4EHSD17B10CES2 | |
| SCHEMBL12497980 | 0.83 | CES2 (0.50) | ALDH1A1HPGDKDM4EHSD17B10CES2 | |
| SCHEMBL28987797 | 0.83 | CES2 (0.50) | ALDH1A1HPGDKDM4EHSD17B10CES2 | |
| SCHEMBL460066 | 0.82 | KDM4E (0.69) | ALDH1A1HPGDKDM4EHSD17B10CES2 | |
| SCHEMBL28695556 | 0.81 | TDP1 (0.56) | ALDH1A1HPGDHSD17B10SRD5A2 | |
| SCHEMBL23141224 | 0.79 | CFTR (0.62) | ALDH1A1HPGDKDM4EHSD17B10CES2 | |
| SCHEMBL43771 | 0.78 | ALDH1A1 (0.59) | ALDH1A1HPGDKDM4EHSD17B10CES2 | |
| SCHEMBL11817225 | 0.78 | ALDH1A1 (0.59) | ALDH1A1HPGDKDM4EHSD17B10CES2 | |
| SCHEMBL503272 | 0.78 | CES2 (0.75) | ALDH1A1HPGDKDM4EHSD17B10CES2 | |
| SCHEMBL16960591 | 0.78 | CES2 (0.44) | ALDH1A1HPGDKDM4EHSD17B10CES2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 131 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116396159-A | Synthesis method of 2,2' -biphenyl dicarboxylic acid compound | 湖南大学 | 2023-07-07 | — | — | CN | claimed |
| EP-3856179-B1 | MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2026-05-13 | — | — | EP | disclosed |
| US-12606522-B2 | Sulfinylaminobenzamide and sulfonylaminobenzamide derivatives | ORSOBIO, INC. (US) | 2026-04-21 | — | — | US | disclosed |
| US-20240409508-A1 | SULFINYLAMINOBENZAMIDE AND SULFONYLAMINOBENZAMIDE DERIVATIVES | ORSOBIO, INC. | 2024-12-12 | — | — | US | disclosed |
| CN-118791407-A | Sulfinylamino group benzamide and process for preparing same Sulfonylamino benzamide derivatives | 奥索生物公司 | 2024-10-18 | — | — | CN | disclosed |
| US-20240327410-A1 | Monoacylglycerol Lipase Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2024-10-03 | — | — | US | disclosed |
| CN-118638096-A | Sulfinylamino group benzamide and process for preparing same Sulfonylamino benzamide derivatives | 奥索生物公司 | 2024-09-13 | — | — | CN | disclosed |
| CN-113164458-B | Monoacylglycerol lipase modulators | 詹森药业有限公司 | 2024-09-13 | — | — | CN | disclosed |
| US-12049439-B2 | Sulfinylaminobenzamide and sulfonylaminobenzamide derivatives | ORSOBIO, INC. (US) | 2024-07-30 | — | — | US | disclosed |
| CN-112204008-B | Sulfonylaminobenzamides and sulfonylaminobenzamide derivatives | 奥索生物公司 | 2024-07-05 | — | — | CN | disclosed |
| WO-2007041494-A2 | CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITORS | MERCK & CO., INC. (US) | 2007-04-12 | — | — | WO | disclosed |
| US-7202364-B2 | Certain phenylacetic acids and derivatives | NOVARTIS, AG (CH) | 2007-04-10 | — | — | US | disclosed |
| EP-1765793-A1 | CETP INHIBITORS | Merck and Co., Inc. (US) | 2007-03-28 | — | — | EP | disclosed |
| US-20060040999-A1 | CETP inhibitors | MERCK SHARP & DOHME LLC | 2006-02-23 | — | — | US | disclosed |
| WO-2006014357-A1 | CETP INHIBITORS | MERCK & CO., INC. (US) | 2006-02-09 | — | — | WO | disclosed |
| WO-2006014413-A1 | CETP INHIBITORS | MERCK & CO., INC. (US) | 2006-02-09 | — | — | WO | disclosed |
| CN-1729157-A | Substituted amino phenylacetic acids, derivatives thereof, their preparation and their use as cyclooxygenase 2 (COX-2) inhibitors | NOVARTIS AG (CH) | 2006-02-01 | — | — | CN | disclosed |
| EP-1567477-A1 | SUBSTITUTED AMINO PHENYLACETIC ACIDS, DERIVATIVES THEREOF, THEIR PREPARATION AND THEIR USE AS CYCLOOXYGENASE 2 (COX-2) INHIBITORS | Novartis AG (CH) | 2005-08-31 | — | — | EP | disclosed |
| US-20040132769-A1 | Certain phenylacetic acids and derivatives | NOVARTIS AG (CH) | 2004-07-08 | — | — | US | disclosed |
| WO-2004048314-A1 | SUBSTITUTED AMINO PHENYLACETIC ACIDS, DERIVATIVES THEREOF, THEIR PREPARATION AND THEIR USE AS CYCLOOXYGENASE 2 (COX-2) INHIBITORS | NOVARTIS AG (CH) | 2004-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060040999-A1 | CETP inhibitors | CETP, APOB, MTTP | ALDH1A1 3887/4885HPGD 2844/4885KDM4E 1437/4885 |
| US-20040132769-A1 | Certain phenylacetic acids and derivatives | CYP2A6, HCAR2, CYP2B6 | ALDH1A1 99/4885HPGD 84/4885KDM4E 3616/4885 |
| US-12049439-B2 | Sulfinylaminobenzamide and sulfonylaminobenzamide derivatives | STS, SULT2A1, SCN2B | ALDH1A1 245/4885HPGD 2345/4885KDM4E 3158/4885 |
| US-12606522-B2 | Sulfinylaminobenzamide and sulfonylaminobenzamide derivatives | NR3C2, NR5A1, SRD5A2 | ALDH1A1 1507/4885HPGD 2085/4885KDM4E 3921/4885 |
| US-20240409508-A1 | SULFINYLAMINOBENZAMIDE AND SULFONYLAMINOBENZAMIDE DERIVATIVES | STS, SULT2A1, SCN2B | ALDH1A1 245/4885HPGD 2345/4885KDM4E 3158/4885 |
| US-20240327410-A1 | Monoacylglycerol Lipase Modulators | MGLL, LPL, PNLIP | ALDH1A1 344/4885HPGD 1080/4885KDM4E 2800/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.